280 related articles for article (PubMed ID: 14532761)
1. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
[TBL] [Abstract][Full Text] [Related]
2. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
Pandit-Taskar N; O'Donoghue JA; Morris MJ; Wills EA; Schwartz LH; Gonen M; Scher HI; Larson SM; Divgi CR
J Nucl Med; 2008 Jul; 49(7):1066-74. PubMed ID: 18552139
[TBL] [Abstract][Full Text] [Related]
3. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Bander NH
J Clin Oncol; 2004 Jul; 22(13):2522-31. PubMed ID: 15173215
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Tagawa ST; Milowsky MI; Morris M; Vallabhajosula S; Christos P; Akhtar NH; Osborne J; Goldsmith SJ; Larson S; Taskar NP; Scher HI; Bander NH; Nanus DM
Clin Cancer Res; 2013 Sep; 19(18):5182-91. PubMed ID: 23714732
[TBL] [Abstract][Full Text] [Related]
11. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
12. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
13. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Nanus DM; Milowsky MI; Kostakoglu L; Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Bander NH
J Urol; 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9. PubMed ID: 14610416
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
17. The utility of monoclonal antibodies in the imaging of prostate cancer.
Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
[TBL] [Abstract][Full Text] [Related]
18. What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
Simone CB; Hahn SM
Clin Cancer Res; 2013 Sep; 19(18):4908-10. PubMed ID: 23926229
[TBL] [Abstract][Full Text] [Related]
19. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
